Best Telehealth for GLP-1 Prescriptions: How to Choose

The telehealth market for GLP-1 medications has expanded faster than almost any other category in digital health. Within a few years, getting a prescription for semaglutide or tirzepatide went from something that required an in-person appointment with a specialist to something a marketing email promises in "under five minutes." Dozens of platforms now compete for the same patients, and they differ enormously — not just in price, but in the one thing that matters most: whether there is real medical care behind the website.

That variation is the problem this guide exists to address. A GLP-1 receptor agonist is a powerful, long-term medication that changes how your gut, pancreas, and appetite circuits behave. Used well, under genuine clinical supervision, it is one of the most effective treatments obesity medicine has ever produced. Used carelessly — dispensed by a form-and-checkout operation with no identifiable prescriber, no follow-up, and an unvetted supply chain — it carries avoidable risk. The difficulty for a patient is that both kinds of provider look broadly similar from the outside. Both have clean websites, reassuring language, and a button that says "get started."

This guide does not rank named companies, and it deliberately avoids quoting specific prices or endorsing specific brands. Those things change constantly — a provider that is excellent this quarter may be acquired, change its pharmacy partner, or alter its clinical model the next. What does not change is the underlying anatomy of good medical care. This is a durable evaluation framework: a set of criteria you can apply to any platform you encounter, in any month, to work out whether you are looking at a medical service or a storefront. For the underlying science these medications rest on, the complete guide to GLP-1 medications is the companion to this piece, and the wider GLP-1 science hub collects the related access and cost articles in one place.

How Telehealth GLP-1 Prescribing Actually Works

To evaluate a telehealth provider, it helps to understand what a legitimate prescribing process is supposed to involve, because the good and the questionable platforms diverge precisely at these steps.

A proper telehealth GLP-1 service begins with a clinical evaluation. You complete an intake that captures your weight and height (for body mass index), your medical history, current medications, and relevant family history. Crucially, that information is then reviewed by a licensed clinician — a physician, nurse practitioner, or physician assistant licensed in your state or country — who decides whether a GLP-1 medication is appropriate for you, and if so, which one and at what starting dose. In a well-run service this review is a genuine clinical judgement, sometimes including a video or phone consultation, and the clinician can decline to prescribe if the medication is not indicated or is unsafe given your history.

Eligibility follows the standard framework in obesity medicine: typically a BMI of 30 or higher, or 27 or higher with a weight-related condition such as type 2 diabetes, hypertension, or obstructive sleep apnoea. A careful provider screens for contraindications — a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, a history of pancreatitis, pregnancy or plans to become pregnant — because these are reasons not to prescribe, or to prescribe only with caution. The detail of who meets these thresholds is covered in who qualifies for a GLP-1 prescription.

If the clinician approves treatment, a prescription is sent to a pharmacy, which dispenses the medication and ships it to you. From there, the medication is started at a low dose and increased in steps over weeks or months — the titration schedule that keeps side effects manageable. A good service stays involved throughout this period: checking in, adjusting the dose, helping you manage nausea, and escalating to a clinician if something goes wrong. A poor service treats the first shipment as the end of the relationship.

The reason these medications are dispensed by prescription rather than sold over the counter is the same reason the quality of the prescriber matters. As Drucker's account of the drug class makes clear, GLP-1 receptor agonists act simultaneously on insulin secretion, gastric emptying, and central appetite circuits (Drucker, 2018). That breadth of action is what makes them effective, and also why they need a clinician's judgement: the same slowed gastric emptying that produces satiety produces nausea, and the same appetite suppression that drives weight loss can, unmanaged, lead to inadequate nutrition.

What Good Clinical Care Looks Like

The single most useful distinction when evaluating a provider is between a medical service and a fulfilment service. A medical service is organised around a clinician-patient relationship: someone is responsible for your care, knows your history, and remains reachable. A fulfilment service is organised around moving product: the clinical step exists mainly to satisfy the legal minimum for issuing a prescription, and everything is optimised for speed of checkout.

Several features mark the difference. A real medical service can tell you who your prescriber is and how to reach them. It conducts an evaluation substantial enough to catch contraindications, rather than a questionnaire engineered to approve almost everyone. It supports dose titration actively rather than shipping a fixed dose and leaving you to manage. It has a defined pathway for side effects and complications, so that if you develop severe vomiting, signs of pancreatitis, or any other concerning symptom, you can reach a clinician quickly. And it treats the prescription as the beginning of an ongoing relationship — appropriate, given that the evidence frames obesity as a chronic condition requiring continued management rather than a problem solved in a single transaction.

That chronic-disease framing is not a marketing flourish; it follows from the biology. The STEP 4 trial showed that when semaglutide was withdrawn, participants regained roughly two-thirds of the weight they had lost, while those who continued kept losing (Rubino et al., 2021). The STEP 1 trial extension found the same pattern after the drug was stopped (Wilding et al., 2022). The body defends its prior weight through elevated hunger signalling and reduced energy expenditure — adaptations documented across decades of research, from Leibel's measurements of falling energy expenditure after weight loss (Leibel et al., 1995) to Sumithran's finding that appetite hormones remain dysregulated a full year after dieting (Sumithran et al., 2011), to Anderson's meta-analysis showing that people maintain only about a quarter of their lost weight at five years (Anderson et al., 2001). A provider that understands this builds for continuity; a provider that does not sells you a few months and moves on.

The Evaluation Framework: Eight Criteria

The table below distils the assessment into eight criteria. For each, it states why the criterion matters, the green flags that suggest a provider takes it seriously, and the red flags that should give you pause. No single red flag is necessarily disqualifying, but a pattern of them is.

Criterion	Why it matters	Green flags	Red flags
Licensed clinician access	A GLP-1 prescription is a medical decision that requires a prescriber licensed where you live. You need to know who is responsible for your care.	Named prescriber or care team; credentials verifiable; licensed in your state/country; a way to message or speak with them after you start.	No identifiable prescriber; "doctors" who can't be named or verified; no contact pathway once you've paid; prescriber licensed somewhere unrelated to you.
Real medical evaluation	The evaluation is what catches contraindications and confirms the medication is appropriate. A checkout-only flow skips the part that protects you.	Detailed history; screening for thyroid cancer, MEN2, pancreatitis, pregnancy; questions about other medications; clinician can decline to prescribe.	One-page form engineered to approve everyone; no contraindication screening; instant approval; no path to being told "this isn't right for you."
Lab work	Baseline labs (e.g. metabolic panel, HbA1c, kidney function) inform safe prescribing and let problems be caught early.	Offers or requires relevant baseline labs; reviews results before or shortly after starting; can order follow-up testing.	Never mentions labs; explicitly markets "no labs, no bloodwork" as a selling point; no interest in your baseline health.
Dose titration support	Starting low and increasing in steps is how side effects are kept tolerable. Rushed or unsupported titration is a leading cause of people stopping.	Structured titration schedule; check-ins at dose increases; willingness to slow down or hold a dose; guidance on managing nausea.	Fixed dose with no plan to adjust; pressure to escalate quickly; no support when side effects appear; "set and forget" shipments.
Transparent pricing	Hidden fees, auto-renewing subscriptions, and unclear cancellation terms are how costs balloon and patients get trapped.	Clear monthly cost; what's included (medication, consults, support); easy cancellation; no surprise charges.	Prices hidden until checkout; hard-to-cancel subscriptions; long lock-in contracts; vague bundling that obscures the real cost.
Compounded vs brand sourcing	The source and form of the drug affects safety and consistency. You should know exactly what you are getting and where it comes from.	States clearly whether the product is brand-name or compounded; names the dispensing pharmacy; pharmacy is licensed and verifiable; explains the difference.	Won't say whether it's brand or compounded; vague or unnamed pharmacy; sources from outside the regulated supply chain; markets "research-grade" or unbranded vials.
Continuity of care	These medications are long-term. Weight returns when they stop, so ongoing management — not a one-off sale — is what the biology requires.	Ongoing relationship; periodic reviews; coordinates with your regular doctor; plan for maintenance and for what happens if you stop.	Transactional, ship-and-disappear model; no follow-up; no plan beyond the first few months; no coordination with your other care.
Data privacy	You're handing over sensitive health data. How it's stored, shared, and used for advertising is a real consideration.	Clear, readable privacy policy; complies with applicable health-privacy law; doesn't sell or share data with advertisers; lets you delete your data.	No clear policy; broad consent to share/sell data; tracking and ad-targeting on health information; no way to delete your records.

Used together, these criteria separate providers reliably. A platform that names its clinicians, screens you properly, supports titration, is transparent about price and drug source, and stays involved over time is doing the things a medical service does. A platform that approves everyone in minutes, hides its prices, won't say where the drug comes from, and vanishes after shipping is doing the things a storefront does.

Compounded Versus Brand: What to Understand

One area deserves more explanation than a table cell allows, because it is where some of the largest quality differences hide: the question of whether a provider dispenses brand-name medication or a compounded version.

Brand-name GLP-1 medications are manufactured by the original pharmaceutical companies, subject to the full regulatory approval and quality-control process. Compounded versions are prepared by compounding pharmacies, which traditionally exist to make customised formulations — for example, a liquid version of a drug for a patient who cannot swallow pills. During periods when brand-name supply could not meet demand, compounded semaglutide and tirzepatide became widely available through telehealth, often at substantially lower prices, which is a large part of why the market grew so fast.

Compounding occupies a different regulatory position from brand manufacturing. Compounded products are not individually reviewed for safety and efficacy the way an approved drug is, and quality depends heavily on the standards of the specific pharmacy preparing them. Some compounding pharmacies are rigorous, licensed, and reputable; others are not, and there have been documented concerns about dosing errors, incorrect concentrations, and products sourced from outside the regulated supply chain entirely — including unbranded "research" vials sold with disclaimers that they are "not for human use." The legal status of compounded GLP-1 medications has also shifted as brand-name supply normalised, which affects what providers can legitimately offer.

None of this makes compounded medication categorically unacceptable — for some patients it is a legitimate, clinician-supervised route to access. But it raises the importance of two of the framework criteria. First, the provider should tell you clearly whether you are getting brand-name or compounded medication; refusing to say is itself a red flag. Second, if it is compounded, the provider should name the dispensing pharmacy so you can verify it is licensed and in good standing. A provider that is evasive about what it is selling and where it comes from has failed the most basic test of a medical service. The broader cost picture, including how compounded and brand pricing compare, is covered in GLP-1 cost without insurance.

Safety and Red Flags

Beyond the criteria table, a handful of patterns recur often enough among low-quality operations to be worth naming directly. Treat any of these as a reason to look harder, and a cluster of them as a reason to look elsewhere.

Approval that is too fast and too easy. If a platform approves essentially everyone within minutes, with no meaningful evaluation and no possibility of being declined, the clinical step is decorative. The value of a real evaluation is precisely that it can say no — to someone with a contraindication, or for whom the medication is not appropriate. A process incapable of saying no is not protecting you.

"No labs, no questions" as a selling point. Marketing the absence of clinical diligence — no bloodwork, no medical history, no consultation — as a convenience is a sign that convenience has been prioritised over safety. Lab work and history-taking are not bureaucratic friction; they are how a prescriber catches the things that make these drugs unsafe for a given person.

Pressure and urgency. Countdown timers, "limited stock," and pressure to escalate your dose quickly are sales tactics, not clinical ones. Titration is meant to be paced to your tolerance, not to a subscription calendar. Rushed escalation is one of the most common reasons people experience side effects severe enough to quit.

No pathway for problems. Before you start, you should know exactly how to reach a clinician if something goes wrong — persistent vomiting, severe abdominal pain that could signal pancreatitis, signs of gallbladder disease, or any reaction that worries you. A provider with no after-hours pathway and no clear escalation route has left you without support for exactly the situations that matter most.

Evasiveness about the drug. If a provider will not tell you whether the medication is brand or compounded, or will not name the pharmacy, that opacity is the warning. Legitimate services are straightforward about what they dispense.

It is also worth remembering what the medications themselves require regardless of provider. They are titrated for a reason, the gastrointestinal side effects are real if usually manageable, and rarer serious effects — pancreatitis, gallbladder disease, and the thyroid-tumour contraindication drawn from rodent studies — are part of why a clinician belongs in the loop. The efficacy that makes these drugs worth the trouble is well established: in the STEP 1 trial, semaglutide produced a mean weight loss of about 15% over 68 weeks (Wilding et al., 2021), and in SURMOUNT-1, the highest dose of tirzepatide produced a mean loss of roughly 21% (Jastreboff et al., 2022). That effect comes from a genuine alteration of appetite biology — including a reduced reward-system response to food cues (van Bloemendaal et al., 2014) — which is exactly why it warrants real medical supervision rather than a checkout flow.

Cost Transparency and the Subscription Trap

Pricing in this market is deliberately confusing, and the confusion is sometimes the business model. Because prices and programme terms change constantly, this guide will not quote specific figures — but the structure of the costs is stable enough to plan around.

Telehealth GLP-1 programmes typically charge a recurring monthly fee that bundles some combination of the medication, the clinical consultation, and ongoing support. The headline number is not always the whole cost. Watch for membership or platform fees layered on top of the medication price, charges for consultations billed separately, and the difference between an introductory rate and the ongoing rate once a promotional period ends. The most important structural feature to check is the subscription itself: how it renews, how easily it cancels, and whether you are committed to a fixed term. A meaningful share of complaints about these services concerns difficulty cancelling and unexpected recurring charges, not the medication.

Transparency, then, is itself a quality signal. A provider that states the full monthly cost up front, makes clear what is included, and lets you cancel without friction is behaving like a service confident in its value. One that hides the price until checkout, obscures the real cost in a bundle, or makes cancellation deliberately hard is telling you something about how it sees the relationship. Whether your costs can be reduced through coverage is a separate question — many people overlook routes that exist. The companion guides on getting GLP-1 covered by insurance and prior authorization tips cover the levers that can lower what you actually pay.

Questions to Ask Before You Commit

The framework becomes practical when you turn it into questions. Before signing up with any provider, you should be able to get clear answers to the following. A good service answers them readily; a poor one deflects.

• Who is my prescriber, and are they licensed where I live? You should get a name or an identifiable care team and confirmation of licensing in your state or country.
• What does the evaluation involve, and can I be declined? A service that can say no is a service doing real screening.
• Is the medication brand-name or compounded, and which pharmacy dispenses it? Evasion here is disqualifying.
• How does titration work, and what support do I get at each dose increase? Look for a structured schedule and active check-ins, not a fixed shipment.
• How do I reach a clinician if I have side effects or an emergency? There should be a defined, reasonably prompt pathway.
• What is the full monthly cost, what's included, and how do I cancel? The complete number, the inclusions, and the exit should all be clear before you pay.
• What labs do you require or offer, and will you review them? Baseline testing is a marker of diligence, not friction.
• How is my health data stored and used, and can I delete it? Read the privacy policy specifically for whether data is shared with or sold to advertisers.
• Will you coordinate with my regular doctor? Continuity of care across your providers is a sign of a service built for the long term.

One further step costs nothing and protects a great deal: prepare for the medication itself as carefully as you choose the provider. Knowing the contraindications, the side-effect timeline, and the nutrition and protein considerations before you start makes you a better-informed patient and a harder one to mislead. The GLP-1 checklist before starting is a practical place to do that groundwork.

The Bottom Line

The convenience of telehealth is real, and for many people it has made an effective treatment accessible that would otherwise have been out of reach. But convenience and quality are not the same thing, and the gap between them in this market is wide. The providers worth your trust are the ones that behave like medical services: a named, licensed clinician; a genuine evaluation that can decline; transparency about the drug and its source; structured titration support; a pathway for problems; honest pricing; and a relationship built to continue, because the biology of weight regain means continuation is usually what these medications require.

You do not need to memorise a list of approved companies — that list would be out of date by the time you read it. You need the framework. Apply these eight criteria and the questions that flow from them to whatever provider is in front of you, and the difference between a medical service and a storefront becomes visible quickly. The medication is genuinely effective. Make sure the care around it is too.

This article is educational and not medical advice. Whether a GLP-1 medication is appropriate for you, and which provider and product suit your situation, are decisions to make with a qualified clinician who knows your history.